Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.16 -0.13 (-0.39%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital ↗

March 31, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,...

Via Benzinga

This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗

March 24, 2022

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗

March 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗

March 14, 2022

Sentiment was low heading into the study and analysts aren't hopeful for other tests.

Via Investor's Business Daily

Recap: Alkermes Q4 Earnings ↗

February 16, 2022

Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 16, 2022 ↗

February 16, 2022

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

The Ruble Is Rubble ↗

March 03, 2022

MSCI says Russian companies are

Via Talk Markets

Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer ↗

February 17, 2022

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant...

Via Benzinga

Alkermes's Return On Capital Employed Overview ↗

February 17, 2022

According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%...

Via Benzinga

56 Biggest Movers From Yesterday ↗

February 17, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...

Via Benzinga

Why Are Alkermes Shares Trading Higher Today? ↗

February 16, 2022

Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 16, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...

Via Benzinga

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗

February 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...

Via Benzinga

Earnings Preview For Alkermes ↗

February 15, 2022

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia ↗

February 08, 2022

Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)

Via Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022 ↗

January 27, 2022

Upgrades

Via Benzinga

BioCorRx Aims To Help Combat Opioid Crisis With Implantable Naltrexone Drug Candidate BICX104 ↗

January 24, 2022

Image provided by BioCorRx of a naltrexone pellet This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be...

Via Benzinga

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

Early Monday Report - More Moves Out Of China ↗

January 09, 2022

Before it even turned Monday in the West, China insurers are feeling the heat.

Via Talk Markets

Happy New Year - Sunday Edition ↗

January 02, 2022

Starting a new year - we look at tech, pharma and mining stocks and their goings-on.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗

December 01, 2021

Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV

Via Benzinga

75 Biggest Movers From Yesterday ↗

November 10, 2021

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...

Via Benzinga

Janssen Partially Terminates Nanoparticle License Agreement With Alkermes ↗

November 09, 2021

Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its...

Via Benzinga

Why Alkermes Stock Is Sinking Today ↗

November 09, 2021

Johnson & Johnson partly ended two licensing agreements with the company.

Via The Motley Fool

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

7 A-Rated Healthcare Stocks to Buy for the Long Haul ↗

November 01, 2021

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future.

Via InvestorPlace

10 Biggest Price Target Changes For Thursday ↗

October 28, 2021

Oppenheimer lowered Teladoc Health, Inc. (NYSE:TDOC

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alkermes plc - Ordinary Shares (NQ:ALKS)

Headline News about Alkermes plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today